The potential role of statins in severe sepsis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Sepsis is the tenth leading cause of death in the United States (Hoyert et al. 2001) and has a mortality rate of up to 70% (Angus et al. 2001; Annane et al. 2003). Inpatients with sepsis have a 26-fold increased risk of death compared to intensive care unit subjects without sepsis (Annane et al. 2003). New medications are urgently needed to prevent and treat sepsis since only a few new classes of antibiotics have been added to the armamentarium in the past ten years, and only one new class of medication specifically targeting sepsis (drotrecogin-alfa) has been added (Bernard et al. 2001). Recently, several classes of medications including HMG-CoA reductase inhibitors (statins) have been found to attenuate the systemic inflammatory response (de Bont et al. 1998; Jialal et al. 2001; Musial et al. 2001; Ridker et al. 1998; Rosenson and Tangney 1998; Rosenson et al. 1999; Strandberg et al. 1999). In addition, statins have been demonstrated to have protective endothelial effects, influence inflammatory cell signaling, directly effect T-cell activity, and influence the nitric oxide balance to promote hemodynamic stability (Almog 2003; Hothersall et al. 2006; Terblanche et al. 2007). Several epidemiologic studies have demonstrated that subjects receiving statins hospitalized with bacteremia and community-acquired pneumonia have improved clinical outcomes, or decreased incidence of sepsis (Almog et al. 2004, 2007; Fernandez et al. 2006; Frost et al. 2007; Gupta et al. 2007; Hackam et al. 2006; Kruger et al. 2006; Liappis et al. 2001; Martin et al. 2007; Mortensen et al. 2005a,b; Schlienger et al. 2007; Thomsen et al. 2006; Yang et al. 2007). The purpose of this article is to review the scientific literature regarding the potential role of statins in the prevention and/or treatment of severe sepsis.

Original languageEnglish (US)
Title of host publicationSepsis: New Strategies for Management
PublisherSpringer Berlin Heidelberg
Pages19-28
Number of pages10
ISBN (Print)9783540790006
DOIs
StatePublished - 2008

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Sepsis
Bacteremia
Intensive Care Units
Inpatients
Epidemiologic Studies
Cause of Death
Pneumonia
Nitric Oxide
Hemodynamics
Anti-Bacterial Agents
T-Lymphocytes
Mortality
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mortensen, E. M., Restrepo, M., & Anzueto, A. R. (2008). The potential role of statins in severe sepsis. In Sepsis: New Strategies for Management (pp. 19-28). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-79001-3_2

The potential role of statins in severe sepsis. / Mortensen, Eric M.; Restrepo, Marcos; Anzueto, Antonio R.

Sepsis: New Strategies for Management. Springer Berlin Heidelberg, 2008. p. 19-28.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mortensen, EM, Restrepo, M & Anzueto, AR 2008, The potential role of statins in severe sepsis. in Sepsis: New Strategies for Management. Springer Berlin Heidelberg, pp. 19-28. https://doi.org/10.1007/978-3-540-79001-3_2
Mortensen EM, Restrepo M, Anzueto AR. The potential role of statins in severe sepsis. In Sepsis: New Strategies for Management. Springer Berlin Heidelberg. 2008. p. 19-28 https://doi.org/10.1007/978-3-540-79001-3_2
Mortensen, Eric M. ; Restrepo, Marcos ; Anzueto, Antonio R. / The potential role of statins in severe sepsis. Sepsis: New Strategies for Management. Springer Berlin Heidelberg, 2008. pp. 19-28
@inbook{f6ba82166c69475497a15fcc3e9934ab,
title = "The potential role of statins in severe sepsis",
abstract = "Sepsis is the tenth leading cause of death in the United States (Hoyert et al. 2001) and has a mortality rate of up to 70{\%} (Angus et al. 2001; Annane et al. 2003). Inpatients with sepsis have a 26-fold increased risk of death compared to intensive care unit subjects without sepsis (Annane et al. 2003). New medications are urgently needed to prevent and treat sepsis since only a few new classes of antibiotics have been added to the armamentarium in the past ten years, and only one new class of medication specifically targeting sepsis (drotrecogin-alfa) has been added (Bernard et al. 2001). Recently, several classes of medications including HMG-CoA reductase inhibitors (statins) have been found to attenuate the systemic inflammatory response (de Bont et al. 1998; Jialal et al. 2001; Musial et al. 2001; Ridker et al. 1998; Rosenson and Tangney 1998; Rosenson et al. 1999; Strandberg et al. 1999). In addition, statins have been demonstrated to have protective endothelial effects, influence inflammatory cell signaling, directly effect T-cell activity, and influence the nitric oxide balance to promote hemodynamic stability (Almog 2003; Hothersall et al. 2006; Terblanche et al. 2007). Several epidemiologic studies have demonstrated that subjects receiving statins hospitalized with bacteremia and community-acquired pneumonia have improved clinical outcomes, or decreased incidence of sepsis (Almog et al. 2004, 2007; Fernandez et al. 2006; Frost et al. 2007; Gupta et al. 2007; Hackam et al. 2006; Kruger et al. 2006; Liappis et al. 2001; Martin et al. 2007; Mortensen et al. 2005a,b; Schlienger et al. 2007; Thomsen et al. 2006; Yang et al. 2007). The purpose of this article is to review the scientific literature regarding the potential role of statins in the prevention and/or treatment of severe sepsis.",
author = "Mortensen, {Eric M.} and Marcos Restrepo and Anzueto, {Antonio R}",
year = "2008",
doi = "10.1007/978-3-540-79001-3_2",
language = "English (US)",
isbn = "9783540790006",
pages = "19--28",
booktitle = "Sepsis: New Strategies for Management",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - The potential role of statins in severe sepsis

AU - Mortensen, Eric M.

AU - Restrepo, Marcos

AU - Anzueto, Antonio R

PY - 2008

Y1 - 2008

N2 - Sepsis is the tenth leading cause of death in the United States (Hoyert et al. 2001) and has a mortality rate of up to 70% (Angus et al. 2001; Annane et al. 2003). Inpatients with sepsis have a 26-fold increased risk of death compared to intensive care unit subjects without sepsis (Annane et al. 2003). New medications are urgently needed to prevent and treat sepsis since only a few new classes of antibiotics have been added to the armamentarium in the past ten years, and only one new class of medication specifically targeting sepsis (drotrecogin-alfa) has been added (Bernard et al. 2001). Recently, several classes of medications including HMG-CoA reductase inhibitors (statins) have been found to attenuate the systemic inflammatory response (de Bont et al. 1998; Jialal et al. 2001; Musial et al. 2001; Ridker et al. 1998; Rosenson and Tangney 1998; Rosenson et al. 1999; Strandberg et al. 1999). In addition, statins have been demonstrated to have protective endothelial effects, influence inflammatory cell signaling, directly effect T-cell activity, and influence the nitric oxide balance to promote hemodynamic stability (Almog 2003; Hothersall et al. 2006; Terblanche et al. 2007). Several epidemiologic studies have demonstrated that subjects receiving statins hospitalized with bacteremia and community-acquired pneumonia have improved clinical outcomes, or decreased incidence of sepsis (Almog et al. 2004, 2007; Fernandez et al. 2006; Frost et al. 2007; Gupta et al. 2007; Hackam et al. 2006; Kruger et al. 2006; Liappis et al. 2001; Martin et al. 2007; Mortensen et al. 2005a,b; Schlienger et al. 2007; Thomsen et al. 2006; Yang et al. 2007). The purpose of this article is to review the scientific literature regarding the potential role of statins in the prevention and/or treatment of severe sepsis.

AB - Sepsis is the tenth leading cause of death in the United States (Hoyert et al. 2001) and has a mortality rate of up to 70% (Angus et al. 2001; Annane et al. 2003). Inpatients with sepsis have a 26-fold increased risk of death compared to intensive care unit subjects without sepsis (Annane et al. 2003). New medications are urgently needed to prevent and treat sepsis since only a few new classes of antibiotics have been added to the armamentarium in the past ten years, and only one new class of medication specifically targeting sepsis (drotrecogin-alfa) has been added (Bernard et al. 2001). Recently, several classes of medications including HMG-CoA reductase inhibitors (statins) have been found to attenuate the systemic inflammatory response (de Bont et al. 1998; Jialal et al. 2001; Musial et al. 2001; Ridker et al. 1998; Rosenson and Tangney 1998; Rosenson et al. 1999; Strandberg et al. 1999). In addition, statins have been demonstrated to have protective endothelial effects, influence inflammatory cell signaling, directly effect T-cell activity, and influence the nitric oxide balance to promote hemodynamic stability (Almog 2003; Hothersall et al. 2006; Terblanche et al. 2007). Several epidemiologic studies have demonstrated that subjects receiving statins hospitalized with bacteremia and community-acquired pneumonia have improved clinical outcomes, or decreased incidence of sepsis (Almog et al. 2004, 2007; Fernandez et al. 2006; Frost et al. 2007; Gupta et al. 2007; Hackam et al. 2006; Kruger et al. 2006; Liappis et al. 2001; Martin et al. 2007; Mortensen et al. 2005a,b; Schlienger et al. 2007; Thomsen et al. 2006; Yang et al. 2007). The purpose of this article is to review the scientific literature regarding the potential role of statins in the prevention and/or treatment of severe sepsis.

UR - http://www.scopus.com/inward/record.url?scp=84892815829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892815829&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-79001-3_2

DO - 10.1007/978-3-540-79001-3_2

M3 - Chapter

SN - 9783540790006

SP - 19

EP - 28

BT - Sepsis: New Strategies for Management

PB - Springer Berlin Heidelberg

ER -